{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:39:29Z","timestamp":1792593569816,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2023-KH136648"],"award-info":[{"award-number":["RS-2023-KH136648"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00558801"],"award-info":[{"award-number":["RS-2025-00558801"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijbiomac.2026.154804","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:59:27Z","timestamp":1791475167000},"page":"154804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Multivalent protein nanocages improve the safety profile of cluster of differentiation 47 checkpoint blockade"],"prefix":"10.1016","volume":"384","author":[{"given":"Wonkyung","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkyoung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hwan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungkuk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeerk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-San","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Hoon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.154804_bb0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0020","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0025","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117894","article-title":"Advancements in platinum-based anticancer drug development: A comprehensive review of strategies, discoveries, and future perspectives","volume":"112","author":"Sahoo","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050500","article-title":"Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy","volume":"9","author":"Nawara","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.026","article-title":"Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy","volume":"267","author":"Wang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188645","article-title":"Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer","volume":"1877","author":"Tian","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112420","article-title":"Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms","volume":"18","author":"Yamaoka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1504142","article-title":"The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies","volume":"14","author":"Imani","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0060","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0065","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial","volume":"28","author":"Hui","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0070","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0075","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000695","article-title":"Lifting the innate immune barriers to antitumor immunity","volume":"8","author":"Rothlin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0085","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47\u2013SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0090","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/s41467-021-25475-w","article-title":"Structure of the human marker of self 5-transmembrane receptor CD47","volume":"12","author":"Fenalti","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0095","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"don't eat me\" signal of CD47\u2013SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1083\/jcb.200708043","article-title":"Inhibition of \"self\" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells","volume":"180","author":"Tsai","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.immuni.2020.07.008","article-title":"CD47 ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis","volume":"53","author":"Morrissey","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0110","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0115","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0120","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0125","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcmd.2009.01.005","article-title":"Protein 4.2: A complex linker","volume":"42","author":"Satchwell","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.884196","article-title":"A novel affinity engineered anti-CD47 antibody with improved therapeutic index that preserves erythrocytes and normal immune cells","volume":"12","author":"Thaker","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0140","article-title":"Opportunities and challenges for anti-CD47 antibodies in hematological malignancies","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0145","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \"don't eat me\" signal and activating the \"eat me\" signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151611","article-title":"Neonatal Fc receptor (FcRn)-targeted design of protein nanocages for sustained circulation","volume":"357","author":"Lee","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.03.002","article-title":"Bioengineered protein-based nanocage for drug delivery","volume":"106","author":"Lee","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0185","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1038\/am.2016.128","article-title":"Engineering protein nanocages as carriers for biomedical applications","volume":"9","author":"Bhaskar","year":"2017","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jconrel.2022.12.022","article-title":"Protein-based nanocages for vaccine development","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0195","article-title":"Enhancing tumor immunotherapy by multivalent anti-PD-L1 nanobody assembled via ferritin nanocage","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0200","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0362","article-title":"PD-L1\/Lag3 bispecific immune checkpoint blocking nanocage exhibits potent antitumor activity beyond dual blockade of PD-L1 and Lag3","volume":"30","author":"Lee","year":"2026","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0205","article-title":"Nanocage-therapeutics prevailing phagocytosis and immunogenic cell death awakens immunity against cancer","volume":"30","author":"Lee","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0210","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0215","doi-asserted-by":"crossref","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0220","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.1401719","article-title":"Loss of cell surface CD47 clustering formation and binding avidity to SIRP\u03b1 facilitate apoptotic cell clearance by macrophages","volume":"195","author":"Lv","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123166","article-title":"Hierarchical protein nano-crystalline hydrogel with extracellular vesicles for ectopic lymphoid structure formation","volume":"318","author":"Ahn","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1535-7163.MCT-25-0425","article-title":"A novel anti-CD47 antibody TJH2201: Efficacious tumor suppression with reduced RBC toxicity via a SIRP\u03b1-independent mechanism","volume":"25","author":"Zhang","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0235","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077615","article-title":"\"Clustering\" SIRP\u03b1 into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47","volume":"8","author":"Ha","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0245","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1021\/nl403252x","article-title":"Nanoscale ligand spacing influences receptor triggering in T cells and NK cells","volume":"13","author":"Delcassian","year":"2013","journal-title":"Nano Lett."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0250","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1039\/D5NH00412H","article-title":"Pattern and precision: DNA-based mapping of spatial rules for T cell activation","volume":"10","author":"Li","year":"2025","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0255","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bpj.2023.10.013","article-title":"DNA origami: Interrogating the nano-landscape of immune receptor activation","volume":"123","author":"Hou","year":"2024","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0265","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jconrel.2021.03.038","article-title":"Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation","volume":"333","author":"Kim","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-021-04184-w","article-title":"De novo protein design by deep network hallucination","volume":"600","author":"Anishchenko","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0280","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.154804_bb0285","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1039\/D0TB02604B","article-title":"Designed protein- and peptide-based hydrogels for biomedical sciences","volume":"9","author":"Ahn","year":"2021","journal-title":"J. Mater. Chem. B"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026047549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026047549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:45:26Z","timestamp":1792590326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026047549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"alternative-id":["S0141813026047549"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.154804","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent protein nanocages improve the safety profile of cluster of differentiation 47 checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.154804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154804"}}